Department of Nephrology, Princess Alexandra Hospital.
Australasian Kidney Trials Network, University of Queensland.
Nephrology (Carlton). 2019 Dec;24(12):1214-1224. doi: 10.1111/nep.13566. Epub 2019 May 2.
Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of premature mortality, morbidities and complications, which severely impair quality of life. However, patient-centered outcomes are not consistently reported in trials in ADPKD, which can limit shared decision-making. We aimed to identify outcomes important to patients and caregivers and the reasons for their priorities.
Nominal group technique was adopted involving patients with ADPKD and caregivers who were purposively selected from eight centres across Australia, France and the Republic of Korea. Participants identified, ranked and discussed outcomes for trials in ADPKD. We calculated an importance score (0-1) for each outcome and conducted thematic analyses.
Across 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 78 (mean 54.5 years) identified 55 outcomes. The 10 highest ranked outcomes were: kidney function (importance score 0.36), end-stage kidney disease (0.32), survival (0.21), cyst size/growth (0.20), cyst pain/bleeding (0.18), blood pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), mobility/physical function (0.12), and fatigue (0.12). Three themes were identified: threatening semblance of normality, inability to control and making sense of diverse risks.
For patients with ADPKD and their caregivers, kidney function, delayed progression to end-stage kidney disease and survival were the highest priorities, and were focused on achieving normality, and maintaining control over health and lifestyle. Implementing these patient-important outcomes may improve the meaning and relevance of trials to inform clinical care in ADPKD.
常染色体显性多囊肾病(ADPKD)患者的过早死亡率、发病率和并发症风险增加,严重影响生活质量。然而,ADPKD 临床试验中并未一致报告以患者为中心的结局,这可能限制了共同决策。本研究旨在确定对患者和照护者重要的结局及其优先顺序的原因。
采用名义小组技术,从澳大利亚、法国和韩国的 8 个中心有目的地选择 ADPKD 患者和照护者参与。参与者确定、排序并讨论了 ADPKD 临床试验中的结局。我们为每个结局计算了一个重要性得分(0-1),并进行了主题分析。
在 17 个小组中,共有 154 名参与者(121 名患者,33 名照护者),年龄 19 至 78 岁(平均 54.5 岁),确定了 55 个结局。排名前 10 的结局为:肾功能(重要性得分 0.36)、终末期肾病(0.32)、生存(0.21)、囊肿大小/生长(0.20)、囊肿疼痛/出血(0.18)、血压(0.17)、工作能力(0.16)、脑动脉瘤/中风(0.14)、移动性/身体功能(0.12)和疲劳(0.12)。确定了 3 个主题:威胁正常的表象、无法控制和理解多种风险。
对于 ADPKD 患者及其照护者,肾功能、延缓进展为终末期肾病和生存是最重要的优先事项,重点是实现正常化,并保持对健康和生活方式的控制。实施这些患者重要的结局可能会提高临床试验在 ADPKD 中的意义和相关性,从而为临床护理提供信息。